SCHEMBL6510875

SCHEMBL6510875

COC(=O)[C@@H](CC(C)C)Nc1nc(Cl)cc(Nc2cccc(F)c2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPR3 P17342 3/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
SLC2A1 P11166 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ELANE P08246 5/20 0.39
CNR2 P34972 1/20 0.39
RXRA P19793 1/20 0.38
PPARG P37231 1/20 0.38
RXRG P48443 1/20 0.38
PPARD Q03181 1/20 0.38
PPARA Q07869 1/20 0.38
ABCC1 P33527 1/20 0.38
ABCG2 Q9UNQ0 1/20 0.38
DAPK3 O43293 1/20 0.38
JAK2 O60674 1/20 0.38
PRKD3 O94806 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6510872 1.00 NPR3 (0.44) NPR3CYP2C9CYP2C19LMNAPOLB
SCHEMBL6517243 0.90 MAPT (0.43) LMNAPOLBMAPTSLC2A1SMN1; SMN2
SCHEMBL6530469 0.86 NPR3 (0.55) NPR3CYP2C9CYP2C19POLBELANE
SCHEMBL6530463 0.86 NPR3 (0.55) NPR3CYP2C9CYP2C19POLBELANE
SCHEMBL6513867 0.86 SLC2A1 (0.42) NPR3CYP2C9CYP2C19MAPTSLC2A1
SCHEMBL6513858 0.86 SLC2A1 (0.42) NPR3CYP2C9CYP2C19MAPTSLC2A1
SCHEMBL6507727 0.85 CYP2C9 (0.43) NPR3CYP2C9CYP2C19LMNAPOLB
SCHEMBL6507731 0.85 CYP2C9 (0.43) NPR3CYP2C9CYP2C19LMNAPOLB
SCHEMBL6512117 0.81 CTSK (0.38) CYP2C9CYP2C19LMNAPOLBMAPT
SCHEMBL6512111 0.81 CTSK (0.38) CYP2C9CYP2C19LMNAPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005003103-A2 2, 4, 6-TRI-SUBSTITUTED 6-MEMBERED HETEROCYCLES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES ASTRAZENECA AB (SE) 2005-01-13 WO disclosed